
High-Cost Blood Cancer Drugs Deliver High Value
Amid the growing debate about the high price of powerful new drugs in the United States, a recent analysis suggests that breakthrough therapies for blood cancers may, in many cases and with some important caveats, provide reasonable value for money spent.
Amid the growing debate about the high price of powerful new drugs in the United States, a recent analysis suggests that breakthrough therapies for blood cancers may, in many cases and with some important caveats, provide reasonable value for money spent.
Researchers present this viewpoint, based upon a comprehensive
Read the press release from the American Society of Hematology:
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.